Treatment of Thymic Carcinoma at Masaoka-Koga Stage IVB with Distant Metastasis

Clinical Scenario

This protocol applies to thymic carcinoma classified as Masaoka-Koga stage IVB (TNM stage IVB), defined by lymphogenous or haematogenous distant metastasis — the most advanced disease stage.

Stage & Treatment Context

At stage IVB, disease is advanced and not amenable to curative resection or definitive radiotherapy. Current evidence-based guidelines recommend chemotherapy as the single treatment modality in this non-resectable, non-irradiable, metastatic setting.

Treatment Approach (Partial Overview)

Subsequent-line chemotherapy options exist for this stage — the specific agents and selection criteria are detailed in the full structured protocol.

Full regimen details, agent sequencing, and clinical decision criteria are available via the protocol below.

Instant Access to Structured Evidence-Based Regimens

References

DOI: 10.1093/annonc/mdv277

Treatment algorithm for metastatic thymic tumour (Masaoka-Koga stage IVB, TNM stage IVB).

Chemotherapy should be offered as single modality treatment in advanced, non-resectable, non-irradiable or metastatic (stage IVB) thymic epithelial tumours.

Options for subsequent lines include pemetrexed [78] [III, B] and oral etoposide.

View source ↗